Literature DB >> 11233558

Uptake mechanisms of L-3-[125I]iodo-alpha-methyl-tyrosine in a human small-cell lung cancer cell line: comparison with L-1.

P L Jager1, E G de Vries, D A Piers, H Timmer-Bosscha.   

Abstract

The radiolabelled amino acid analogue L-3-[125I]iodo-alpha-methyl-tyrosine (IMT) is under evaluation in brain tumours, where it reflects amino acid transport activity, but is also taken up in many other tumour types. This study investigated the uptake mechanism of IMT in tumour cells not derived from brain tumours, in comparison with the native amino acid 14C-tyrosine (Tyr) from which IMT is derived. Human GLC4 small-cell lung cancer cells in log-phase were incubated with IMT and Tyr. Tracer uptake was determined in various buffers, incubation periods, concentrations of specific amino acid transport blockers, pH and temperature. IMT uptake was very fast, reaching a plateau within 5 min, while Tyr kept on accumulating for > 60 min. Based on steady-state experiments, > 90% of IMT uptake could be attributed to amino acid transport activity. The L transport system was the most important, both for IMT and Tyr. IMT uptake into GLC4 tumour cells is almost completely the result of amino acid transport activity (especially the L system) and is very similar to Tyr uptake. Therefore, also outside the brain, IMT is a metabolic tracer that may reflect the increased amino acid transport that is characteristic for malignant tumours.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11233558     DOI: 10.1097/00006231-200101000-00013

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  1 in total

1.  123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.

Authors:  Veerle Kersemans; Bart Cornelissen; Ken Kersemans; Matthias Bauwens; Rudi A Dierckx; Bart De Spiegeleer; John Mertens; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.